The monocyte-to-lymphocyte ratio: Sex-specific differences in the tuberculosis disease spectrum, diagnostic indices and defining normal ranges

Thomas S. Buttle1am, Claire Y. Hummerstone1‡, Thippeswamy Billahalli1‡, Richard J. B. Ward1‡, Korina E. Barnes2mb, Natalie J. Marshall2, Viktoria C. Spong1‡, Graham H. Bothamley1,3,4*  

1 Department of Respiratory Medicine, Homerton University Hospital, London, United Kingdom, 2 Microbiology Department, Homerton University Hospital, London, United Kingdom, 3 Department of Immunobiology, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, 4 Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom  

* These authors contributed equally to this work. 
‡ These authors also contributed equally to this work.  
* g.bothamley@nhs.net

Abstract

Background
The monocyte-to-lymphocyte ratio (MLR) has been advocated as a biomarker in tuberculosis. Our objective was to evaluate its clinical value and associations.

Methods
Blood counts, inflammatory markers and clinical parameters were measured in patients with and those screened for tuberculosis. Complete blood counts (CBCs) from a multi-ethnic population aged 16 to 65 years were evaluated; a sub-group with normal hematological indices was used to define the range of MLRs.

Results
Multivariate analysis in proven tuberculosis (n = 264) indicated MLR associated with low serum albumin, high white cell counts and a positive culture; values were higher in sputum smear-positive pulmonary tuberculosis (S+PTB). Analysis in S+PTB (n = 296) showed higher MLRs in males and those with high neutrophil counts, low serum albumin and high C-reactive protein. The diagnostic value of MLRs was assessed by comparing notified patients with TB (n = 264) with denotified cases (n = 50), active case-finding in non-contacts (TB n = 111 and LTBI n = 373) and contacts of S+PTB (n = 149) with S+PTB found at screening (n = 75). Sensitivities and specificities ranged from 58.0–62.5% and 50.0–70.0% respectively for
optimal cut-off values, defined by ROC curves. In CBCs obtained over one month, ratios correlated with neutrophil counts ($\rho = 0.48$, $P < 0.00001$, $n = 14,573$; MLR = 0.45 at 8–8.9 x 10^9/L) and were higher in males than females ($P < 0.0001$). The MLR range (mean ± 2SD) in those with normal hematological indices ($n = 3921$: females 0.122–0.474; males 0.136–0.505) paralleled LTBI MLRs. Ratios did not predict death ($n = 29$) nor response to treatment ($n = 178$ S+PTB with follow-up CBCs). Ratios were higher in males than female in the 16–45 years age group, where immune differences due to sex hormones are likely greatest.

Conclusions
Severe tuberculosis and male sex associated with high MLRs; the same variables likely affect the performance of other biomarkers. The ratio performed poorly as a clinical aid.

Introduction
Tuberculosis (TB) was declared a global health emergency by the World Health Organization in April 1993 and remains a leading cause of death and disease [1]. The microbiological diagnosis of TB has advanced considerably through molecular testing [2]. The use of two proteins found in Mycobacterium tuberculosis but not in Bacille Calmette-Guérin (BCG) in interferon-gamma release assays (IGRAs) has improved the specificity of diagnosing latent tuberculosis infection (LTBI) [3].

Many non-specific biomarkers have been proposed to identify those with a positive IGRA who will develop active TB [4], those with sub-clinical disease (i.e., those without symptoms often with a normal chest x-ray without raised inflammatory markers) [5], those likely to die from TB [6], those whose genotype might suggest a protective response to Mycobacterium tuberculosis [7] and transcriptomic measures of risk, diagnosis and treatment response [8]. The monocyte-to-lymphocyte ratio (MLR) has experienced a revived interest as a biomarker. Monocytes are released from the bone marrow into the bloodstream in sepsis and other infections and migrate to foci of infection where they mature into macrophages [9]. Lymphocytes are responsible for the cellular and antibody responses to infection [10]; for instance, the low number of CD4+ T lymphocytes in HIV infection are responsible for the susceptibility to infections. Originally identified in TB patients, a rabbit model suggested that both high and low MLRs might be markers for TB progression [11]. In a mouse model, high MLRs were associated with impaired protection of BCG against TB [12]. An elevated MLR was thought to correlate with different stages of TB disease [13], identify those with HIV infection most likely to develop active TB [14, 15], contacts likely to develop active TB [16] and neonates at risk of TB [17]. In vitro studies with a mycobacterial growth inhibition assay suggested that monocytes and lymphocytes from those with a higher MLR were less able to inhibit the growth of BCG [18]. We, therefore, examined the MLR in patients with TB and LTBI in order to test the hypothesis that such a simple measurement from a complete blood count (CBC) could be of clinical value. Early results were reported in the form of abstracts [19, 20].

Methods
Study design
A retrospective audit of the value of MLRs in patients with or screened for tuberculosis. Research was conducted according to the principles expressed in the Declaration of Helsinki.
TB patients had given informed written consent in the clinical trial Blood Tests in Tuberculosis III, approved by the East London and City Health Authority Research Ethics Committee (P/03/285), registered under the number NIHR 4177. Those screened for TB had given informed written consent in the UK PREDICT TB Study, whose procedures and protocol were approved by the Brent NHS Research Ethics Committee (10/H7017/14). Both gave access to their clinical data and investigations which were used in this study. For those who were screened for participation in these studies or had provided these data taken during normal clinical care but had not been entered into these trials, waivers were given according to the processes set by the UK Research Institute/Medical Research Council/NHS Health Research Authority (http://www.hra-decisiontools.org.uk/ethics/). In addition, for non-participants of the trials, the study was confirmed as an audit and related to quality improvement of clinical care by the local Research and Development Office.

**Setting**
A university district general hospital in an inner-city London borough with a high incidence (falling from 62 to 22 per 100,000 during the period of study) of TB in a multi-ethnic population.

**Participants**
Patients were eligible if they attended TB Clinics between 2005 and 2018 and had a complete blood count (CBC) before the start of any treatment (Fig 1). Children under 16 years of age

![Fig 1. Study populations.](https://doi.org/10.1371/journal.pone.0247745.g001)
were excluded. Active TB was defined by a) a positive culture or by b) a combination of consistent radiology, histology and other tests sufficient for the clinician to notify the patient as having TB and to start a course of treatment without a change in this opinion during treatment nor within the following three years. Contacts were defined by their index case disease type, had spent > 8 h in close proximity to the index case, had attended the TB screening, had a positive IGRA or tuberculin skin test (TST) and were referred for consideration of preventive treatment. LTBI (latent tuberculosis infection) was defined in the screened populations as having a positive IGRA (QuantiFERON > 0.35 IU/mL or positive T-SPOT.TB) or a TST ≥ 15 mm for those with a BCG scar and ≥ 10 mm for those without a BCG scar, and without evidence of active TB. All participants constituted consecutive series (Fig 1).

Control groups included those originally notified as having TB who subsequently proved to have another diagnosis (denotified TB), those with LTBI and a anonymized CBCs analyzed during one month in 2018, in whom those with TB or over 65 years on the grounds of likely co-morbidities were excluded. Only data where the hemoglobin, total red cell count, packed cell volume, mean cell volume, mean cell hemoglobin, platelet count, total white cell count, neutrophils, eosinophils, and basophils were all within normal ranges were used (S2 Table in S2 File).

Variables
TB notification data (age, sex (self-identified), ethnicity (self-identified), country of birth, previous TB, BCG scar, HIV status, diabetes, problem alcohol use, site of disease (patient or index)) were recorded as required by Public Health England for TB as a notifiable disease. Chest radiograph zones out of six and cavitation, sputum smear, days to culture, drug susceptibility test (DST) results, sputum culture at 2 months and end of treatment, and outcome were noted. Deaths were classified as being a) due to TB, i.e. TB was the main cause of death when any other illness at the time was either not present or merely a co-morbidity, such as diabetes; b) TB contributed, i.e. where a clear main cause of death (e.g. pulmonary embolus) was not due to TB, but where TB may have contributed (e.g. rifampicin treatment having induced a hypercoagulable state); or c) clearly unrelated to TB (e.g. a road traffic accident). At screening, reason for attendance, TST and IGRA results were recorded. Blood samples were taken before the start of any treatment, at 2 months and the end of treatment.

Statistical analysis
Data were analyzed with GraphPad Prism version 7 and Microsoft Excel. Univariate analyses were performed with Student’s t-test for continuous predictors and linear regression with categorical predictors. A cut-off of P < 0.1 was employed to define those predictors to be entered into multiple regression analysis (https://stats.blue/Stats_Suite/multiple_linear_regression_calculator.html). Initial examination included all such predictors, which were then removed individually and added back until the best fit model was determined where all coefficients (excluding those for the constant) were significantly greater than zero.

Receiver operating characteristic (ROC) analysis addressed the optimal cut-off MLR and area under the curve (AUC) values (John Hopkins web-based calculator for ROC curves, http://www.rad.jhmi.edu/jeng/javadar/roc/JROCFITi.html [21]). Cut-off MLRs above the 95th and below the 5th centile of the LTBI and the selected anonymized control groups defined diagnostic indices. Chi-squared analysis assessed the significance of MLRs related to these cut-offs. A power calculation showed that to detect a 10% difference between the sensitivities of the MLR with an 80% power at the 5% level required 199 patients in each group if the higher
sensitivity were 20%, or 293 if 30%, but >3000 would be required if the differences between males and females were 5% and the sensitivities lay between 30 and 70% [22].

Results

TB patients

356 patients were notified as having TB over the study period. Twenty were children and 13 had no pre-treatment blood test; 50 were subsequently denotified (Fig 1). The firm alternative diagnoses included cancer (5), pneumonia (2), abscesses (3), Crohn’s disease, glomerulonephritis, lupus and autoimmune encephalitis, non-tuberculous mycobacteria, self-healed tuberculosis and LTBI. Demographic details of the remaining 264 patients are given in Table 1.

MLRs showed a right-sided skew which was improved by log transformation (Fig 2). Those with culture-positive tuberculosis showed more values in the higher ranges than either those who had other forms of TB or had LTBI.

Clinical variables were examined for any significant association with the MLR (Table 2). Interactions were examined and significant associations were found for smear and culture (coefficient 0.36 ± 0.12, p = 0.008). The best fit model was with albumin, white cell count and culture (Table 2 and S1 File). Addition of log-transformed CRP showed a significant interaction with albumin and review of the CRP data indicated many had a CRP of <5 mg/L, which could not be log transformed.

In view of the significant difference in proportion of males and females with TB, the sexes were also analyzed separately. An improved model was found for males using predictors of albumin, culture, HIV co-infection and albumin-to-globulin (AG) ratio, the latter two predictors replacing white cell count (adjusted R-squared 0.395 compared to 0.328; total sum of squares 11.533 compared to 11.974; F = 26.478 compared to 28.003; S1 File). The negative coefficient for HIV in males was associated with low monocyte counts (range 0.1 to 0.5). Surprisingly, the AG ratio did not show a significant interaction with albumin nor with globulin and its coefficient of association with log MLR was positive. No additional improvement above albumin, culture and white cell count could be found for females, although for this group there was a significant interaction between culture and albumin values in females (P = 0.026; S1 File).

MLRs in smear-positive pulmonary tuberculosis (S+PTB)

Patients with S+PTB had shown the highest MLRs (Table 2). We therefore wished to explore whether the preliminary findings in the tuberculosis cohort could be refined by further examining this group (Table 3). In particular, we wanted to know whether the association with the white cell count pertained mainly to the neutrophil count and whether the time to culture, an indicator of bacterial load, was a significant predictor for the MLR. This group would also permit further exploration of other variables that might be associated with higher MLRs, considering the lesser overlap of values from those with LTBI compared to other patients within the TB spectrum. Demographic details of the make-up of this group are given in Table 1 and S1 Table in S2 File. We also expected that this group might shed more light as to why higher MLRs are found in males than females (Fig 3).

Serum albumin remained an important negative predictor of the MLR. The association with neutrophil count was greater than with the white cell count. However, the time to culture was not a predictor. The best fit model for log MLRs included the predictors of sex, albumin, log neutrophil count and log CRP, although there was a significant interaction between albumin and log CRP (P = 0.001; S1 File).
Table 1. Demographic data.

|                      | Active TB 3-yr cohort (n = 264) | Sputum smear-positive TB (n = 296) | Active TB: diagnosis at screening (n = 111) | IGRA+/TST+ contacts of S+PTB (n = 149) | Other IGRA + screened (n = 373) | Control group & one month’s clinics (n = 3921) |
|----------------------|---------------------------------|-----------------------------------|---------------------------------------------|-------------------------------------|---------------------------------|---------------------------------------------|
| **Age:**             |                                 |                                   |                                             |                                     |                                 |                                             |
| median (range), years| 38 (16–88)                      | 36 (16–87)                        | 31 (16–85)                                  | 28 (16–67)                          | 35 (16–73)                      | 38 (16–65)                                  |
| **Female sex:**      | 88 (33)                         | 101 (34)                          | 55 (50)                                     | 72 (48)                             | 196 (53)                        | 2519 (64)                                   |
| **Ethnicity:**       |                                 |                                   |                                             |                                     |                                 |                                             |
| Indian subcontinent  | 80 (30)                         | 41 (14)                           | 25 (23)                                     | 26 (18)                             | 59 (16)                         | NA                                          |
| Black African        | 72 (27)                         | 74 (25)                           | 29 (26)                                     | 44 (30)                             | 196 (53)                        |                                             |
| Afro-Caribbean       | 28 (11)                         | 52 (18)                           | 20 (18)                                     | 14 (14)                             | 14 (4)                          |                                             |
| Turkish/Kurdish      | 23 (9)                          | 18 (6)                            | 1 (1)                                       | 2 (2)                               | 32 (9)                          |                                             |
| White EU             | 18 (7)                          | 25 (9)                            | 2 (2)                                       | 8 (8)                               | 16 (4)                          |                                             |
| White UK             | 19 (7)                          | 41 (14)                           | 10 (9)                                      | 10 (10)                             | 19 (5)                          |                                             |
| Mixed                | 4 (2)                           | 11 (4)                            | 8 (7)                                       | 1 (1)                               | 1 (0)                           |                                             |
| Other                | 20 (8)                          | 34 (12)                           | 16 (15)                                     | 20 (20)                             | 36 (10)                         |                                             |
| **UK-born:**         | 58 (22)                         | 96 (33)                           | 34 (31)                                     | 30 (30)                             | 30 (8)                          | NA                                          |
| **Previous TB:**     | 16 (6)                          | 34 (12)                           | 0 (0)                                       | 0 (0)                               | 1 (0)                           | 1 (0.03)                                    |
| **IGRA:**            |                                 |                                   |                                             |                                     |                                 |                                             |
| Positive             | 137 (84)*                       | 65 (83)*                          | 49 (85)                                     | 146 (98)                            | 300 (95)                        | 25 (32)*                                    |
| Negative             | 24 (15)*                        | 8 (10)*                           | 8 (14)                                      | 1 (1)                               | 0 (0)                           | 41 (53)*                                    |
| Indeterminate        | 2 (1)*                          | 5 (7)*                            | 1 (1)                                       | 0 (0)                               | 0 (0)                           | 4 (5.1)*                                    |
| Not done             | 101 (38)                        | 218 (74)                          | 53 (48)                                     | 2 (1)                               | 0 (0)                           | 15 (16)                                    |
| **BCG:**             | 195 (79)*                       | 208 (74)*                         | 79 (75)*                                    | NA                                  | NA                              | NA                                          |
| **HIV coinfection:** | 9 (4)*                          | 20 (7)*                           | 3 (4)*                                      | 3 (2)                               | 1 (1)                           | NA                                          |
| **Diabetes:**        | 35 (13)                         | 31 (10)                           | 7 (6)                                       | NA                                  | NA                              | NA                                          |
| **Alcohol problem:** | 36 (14)                         | 71 (24)                           | 14 (13)                                     | NA                                  | NA                              | NA                                          |
| **Site of disease:** |                                 |                                   |                                             |                                     |                                 |                                             |
| Pulmonary            | 91 (35)                         | 296 (100)                         | 62 (56)                                     | 1(1)                                | 1(1)                            | 3 (0.08)                                    |
| Extra-pulmonary      | 154 (58)                        | 0 (0)                             | 48 (44)                                     | 2 (1)                               | 0 (0)                           | 4 (0.10)                                    |
| Both                 | 19 (7)                          | 1 (1)                             | 0 (0)                                       | 0 (0)                               | 0 (0)                           |                                             |
| **Drug-resistance:** |                                 |                                   |                                             |                                     |                                 | TB clinics                                   |
| Isoniazid            | 21 (14)*                        | 61 (21)                           | 8 (14)*                                     | NA                                  | NA                              | 0 (0)                                       |
| Rifampicin           | 3 (2)*                          | 6 (2)                             | 1 (2)*                                      | NA                                  | NA                              | 0 (0)                                       |
| Pyrazinamide         | 3 (2)*                          | 2 (1)                             | 0 (0)*                                      | NA                                  | NA                              | 0 (0)                                       |
| MDR-TB               | 1 (1)*                          | 2 (1)                             | 0 (0)*                                      | NA                                  | NA                              | 0 (0)                                       |
| **White blood count**|                                 |                                   |                                             |                                     |                                 |                                             |
| > 11 x 10^9/L        | 30 (11)                         | 51 (17)                           | 7 (6)                                       | 3 (2)                               | 9 (3)                           | 0 (0)                                       |

*indicates percentage of those tested or examined or with available data

TB = tuberculosis; IGRA = interferon-gamma release assay; TST = Tuberculin skin test; NA = not available; UK = United Kingdom; BCG = Bacille Calmette-Guérin; HIV = human immunodeficiency virus; MDR-TB = multidrug-resistant tuberculosis

https://doi.org/10.1371/journal.pone.0247745.t001

Regarding the difference between the sexes, univariate analysis for the different variables is given in Table 4. Notably, variables which show a significant association in females were often not significant in males. This accords with Fig 3A, where the departure from a normal
distribution of values is more apparent in the female S+PTB population. Multiple linear regression analysis for females indicated a best fit model for predictors of log. neutrophil count, albumin-to-globulin ratio, smear and cavities, whereas for males only log. CRP and albumin were valuable and interacted significantly with each other (P = 0.026; S1 File).

Diagnostic indices

Screened persons with LTBI were identified from records of those offered preventive treatment (Fig 1). Contacts of patients with S+PTB (n = 149, 146 without TB) were considered separately (Table 1) as being most likely to develop active disease as a result of recent infection. For more distant infection, only screened individuals with a positive IGRA were included (n = 373, 372 without TB). The MLR for those with LTBI, whether with recent or distant exposure, showed an almost normal distribution with data skewed towards higher ML values (Fig 2A). Log-transformation of the data showed a normal distribution. Assessing receiver-operating characteristics (ROC), the areas under the curve (AUC) varied according to the comparison made (Fig 4). The shortest distance of the curve to the top left-hand corner was used to define the optimal diagnostic indices (Table 5).

Could higher cut-off values of the MLR be useful?

One of the problems in evaluating the literature on the MLRs is to know whether the values that are given might be expected in a “normal” population or do indeed reflect the pathology of TB. Fig 2 indicates a considerable overlap in MLRs between LTBI and active TB, with higher MLRs in those with TB. Comparing the screened LTBI population MLRs, there was no significant difference between contacts and other screening (P-values > 0.4). These two populations of LTBI were therefore combined to develop an upper limit for MLR defined as the log. mean ± 2SD, giving estimated cut-off values of 0.483 (95% CI 0.462 to 0.506) for females and 0.504 (95% CI 0.461 to 0.551) for males.

In order to check the validity of the cut-off values, we examined all anonymized CBCs taken during a single month from those aged 16–65 years (n = 14,573). The MLR increased according to the neutrophil count (ρ = 0.48, P<0.00001); those with an MLR of 0.45
corresponded to those with a neutrophil count of 8–8.9 x 10⁹/L, the laboratory upper limit of normal being 8 x 10⁹/L (S1 Fig). The MLR showed a distribution with a right-sided skew, which was partly normalized by log transformation. A box plot indicated that there still remained a skew toward higher values. Plotting histograms for monocytes and lymphocytes indicated that the former showed an almost normal distribution, but higher monocyte counts were responsible for most of the skewing. A QQ plot confirmed this impression (S2A Fig).

Indeed, high monocyte values have been associated with a number of clinical conditions [23, 24]. On the assumption that other hematological indices might be affected in disease, all samples with any value outside the normal range except for monocytes and lymphocytes were first removed, leaving 4,254 CBCs. If samples were selected with normal hematological indices apart from the monocyte and lymphocyte counts, then upper limit would have been 0.515 (95% CI 0.511 to 0.518) for females and 0.595 (95% CI 0.584 to 0.607) for males and few TB

Table 2. Univariate and multivariable regression analysis of MLRs in tuberculosis.

|                           | Univariate analysis | Multiple linear regression* |
|---------------------------|---------------------|----------------------------|
|                           | n  | MLR                  | P-value       | Coefficient | P-value |
|                           |    | Log mean ± SE        |               | ± SE        |         |
| Sex                       |    |                      |               |             |         |
| Male                      | 176| -0.38 ± 0.020        | 0.1130        |             |         |
| Female                    | 88 | -0.43 ± 0.025        |               |             |         |
| Smear                     |    |                      |               |             |         |
| Positive                  | 67 | -0.25 ± 0.034        | 0.0001        | -0.076 ± 0.13 | 0.555 |
| Negative                  | 197| -0.44 ± 0.017        |               |             |         |
| Culture                   |    |                      |               |             |         |
| Positive                  | 157| -0.33 ± 0.021        | <0.0001       | 0.042 ± 0.038 | 0.268 |
| Negative                  | 107| -0.49 ± 0.022        |               |             |         |
| Site of TB                |    |                      |               |             |         |
| Pulmonary                 | 103| -0.32 ± 0.028        | 0.0002        | -0.06 ± 0.059 | 0.345 |
| Extra-pulmonary           | 161| -0.44 ± 0.019        |               |             |         |
| HIV                       |    |                      |               |             |         |
| Positive                  | 9  | -0.48 ± 0.104        | 0.3442        |             |         |
| Negative                  | 242| -0.39 ± 0.017        |               |             |         |
| Diabetes                  |    |                      |               |             |         |
| Positive                  | 35 | -0.39 ± 0.043        | 0.8813        |             |         |
| Negative                  | 229| -0.39 ± 0.017        |               |             |         |
| Alcohol problem           |    |                      |               |             |         |
| Yes                       | 36 | -0.38 ± 0.047        | 0.5369        |             |         |
| No                        | 228| -0.40 ± 0.017        |               |             |         |
| Drug resistance           |    |                      |               |             |         |
| Yes                       | 28 | -0.41 ± -0.059       | 0.2030        |             |         |
| No                        | 130| -0.34 ± 0.020        |               |             |         |
| BCG scar                  |    |                      |               |             |         |
| Yes                       | 195| -0.39 ± 0.019        | 0.8778        |             |         |
| No                        | 54 | -0.40 ± 0.032        |               |             |         |

Linear regression analysis

|                           | R-squared |
|---------------------------|-----------|
| Age (years)               | 0.0074    |
| White blood count         | 0.0775    |
| Albumin (g/L)             | 0.257     |
| Globulin (g/L)            | 0.0414    |
| Albumin-to-globulin ratio | 0.1758    |
| Log CRP (mg/L)            | 0.2709    |

* Data are given for the initial model with the
  b best-fit model in brackets
  c One outlier with a monocyte count of 8 was excluded

https://doi.org/10.1371/journal.pone.0247745.t002
patients had positive values (S3 Table in S2 File). Moreover, the MLR values were significantly greater than those derived from the LTBI population (P = 0.0003). A QQ plot indicated significant departures from normality, which was especially significant in males (S2B and S2F Fig).

Excluding CBCs to those with a lymphocyte count $> 4 \times 10^9/L$ and monocytes to $> 1 \times 10^9/L$ still showed skewing on a QQ plot and a significant difference from the LTBI population. A monocyte count $> 0.8 \times 10^9/L$ has been associated with significant clinical disease in an emergency room [24]. Using a lymphocyte count $> 4 \times 10^9/L$ and monocytes to $> 0.8 \times 10^9/L$ defined a population close to a normal distribution as well as with the closest approximation to the LTBI population and this was therefore used to define the cut-off limits (S2D, S2G and S3 Figs). CBCs from the TB clinics were removed from this last population. There remained a significant difference in the log MLRs between the sexes (mean (SD): female -0.619 (0.148); male, -0.582 (0.143), P < 0.0001). Defining cut-off values as log mean ± 2SD, for females the upper

---

**Table 3. Univariate and multivariable regression analysis of MLRs in S+PTB.**

|                  | n   | Univariate analysis | Multiple linear regression* |
|------------------|-----|---------------------|----------------------------|
|                  |     | MLR                 | P-value  | Coefficient | P-value  |
|                  |     | Log mean ± SE       | ± SE     | ± SE        |          |
| Sex              |     |                     |          |             |          |
| M                | 193 | -0.19 ± 0.018       | 0.0005   | 0.11 ± 0.034| 0.001    |
| F                | 100 | -0.30 ± 0.028       | (0.1 ± 0.029) | (0.001)    |
| Cavities         |     |                     |          |             |          |
| Present          | 174 | -0.20 ± 0.018       | 0.0827   | 0.10 ± 0.097| 0.307    |
| Absent           | 117 | -0.26 ± 0.027       |          |            |          |
| HIV              |     |                     |          |             |          |
| Positive         | 18  | -0.23 ± 0.078       | 0.9360   |            |          |
| Negative         | 231 | -0.22 ± 0.017       |          |            |          |
| Diabetes         |     |                     |          |             |          |
| Positive         | 31  | -0.24 ± 0.037       | 0.7332   |            |          |
| Negative         | 262 | -0.23 ± 0.017       |          |            |          |
| Alcohol problem  |     |                     |          |             |          |
| Yes              | 74  | -0.22 ± 0.035       | 0.7648   |            |          |
| No               | 219 | -0.23 ± 0.017       |          |            |          |
| Drug resistance  |     |                     |          |             |          |
| Yes              | 66  | -0.23 ± 0.036       | 0.7504   |            |          |
| No               | 221 | -0.22 ± 0.017       |          |            |          |
| BCG scar         |     |                     |          |             |          |
| Yes              | 206 | -0.23 ± 0.018       | 0.6696   |            |          |
| No               | 74  | -0.22 ± 0.030       |          |            |          |

**Linear regression analysis**

|                  | R-squared |
|------------------|-----------|
| Smear grade (df = 4) | 0.0123     |
| Log time to culture (d) | 0.0026     |
| CXR (up to 6 zones)   | 0.0125     |
| Age (years)           | 0.0019     |
| White blood count     | 0.0224     |
| Neutrophil count      | 0.0522     |
| Albumin (g/L)         | 0.1283     |
| Globulin (g/L)        | 0.0476     |
| Albumin-to-globulin ratio | 0.1244   |
| Log CRP (mg/L)        | 0.1327     |

* Data are given for the initial model. The best fit model figures are included in brackets, initially including log CRP (S1 File). However, due to the greater number of missing values, re-analysis was performed without log CRP for other predictors and again analyzing for a best fit model.

https://doi.org/10.1371/journal.pone.0247745.t003
Fig 3. Monocyte-to-lymphocyte ratios and sex. A. Patients with sputum smear-positive pulmonary tuberculosis. B. Patients with tuberculosis excluding sputum smear-positive pulmonary disease. Males show higher values than females.

Table 4. Univariate analysis of variables by sex in S+PTB.

|                | Females |          |          | Males |          |          |
|----------------|---------|----------|----------|-------|----------|----------|
|                | n       | MLR      | P-value  | n     | MLR      | P-value  |
|                | Log mean ± SE |          |          | Log mean ± SE |          |          |
| Cavities       |         |          |          |       |          |          |
| Present        | 53      | -0.25 ± 0.046 | 0.0495   | 122   | -0.20 ± 0.022 | 0.6066   |
| Absent         | 46      | -0.38 ± 0.044 |          | 71    | -0.18 ± 0.031 |          |
| HIV            |         |          |          |       |          |          |
| Positive       | 8       | -0.63 ± 0.21 | 0.0063   | 11    | -0.10 ± 0.10 | 0.2457   |
| Negative       | 78      | -0.29 ± 0.032 |          | 153   | -0.19 ± 0.019 |          |
| Diabetes       |         |          |          |       |          |          |
| Positive       | 13      | -0.26 ± 0.078 | 0.453    | 18    | -0.23 ± 0.033 | 0.4230   |
| Negative       | 88      | -0.33 ± 0.035 |          | 175   | -0.19 ± 0.019 |          |
| Alcohol problem|         |          |          |       |          |          |
| Yes            | 17      | -0.45 ± 0.12 | 0.067    | 58    | -0.18 ± 0.037 | 0.8321   |
| No             | 84      | -0.29 ± 0.029 |          | 135   | -0.19 ± 0.020 |          |
| BCG            |         |          |          |       |          |          |
| Yes            | 63      | -0.34 ± 0.042 | 0.483    | 143   | -0.20 ± 0.021 | 0.3590   |
| No             | 33      | -0.30 ± 0.048 |          | 40    | -0.16 ± 0.036 |          |
| Drug resistance|         |          |          |       |          |          |
| Yes            | 25      | -0.43 ± 0.090 | 0.026    | 42    | -0.15 ± 0.15 | 0.3388   |
| No             | 74      | -0.27 ± 0.030 |          | 147   | -0.20 ± 0.021 |          |
|                |         | Linear regression analysis |          |       |          |          |
|                | R-squared |          |          | R-squared |          |          |
| Smear grade (df = 4) | 94    | 0.0818 | 0.0052 | 181   | 0.0004 | 0.7893 |
| Log time to culture (d) | 97    | 0.0265 | 0.1111 | 186   | 0.0021 | 0.5348 |
| CXR (up to 6 zones) | 96    | 0.0166 | 0.2107 | 185   | 0.0107 | 0.1609 |
| Age (years) | 100     | 0.0006 | 0.8088 | 193   | 0.0059 | 0.2884 |
| White blood count | 100   | 0.0735 | 0.0064 | 193   | 0.0031 | 0.4417 |
| Neutrophil count | 100   | 0.1232 | 0.0028 | 193   | 0.0183 | 0.0627 |
| Log neutrophil count | 100   | 0.1411 | 0.0001 | 193   | 0.0065 | 0.2652 |
| Albumin (g/L) | 98      | 0.1226 | 0.0004 | 190   | 0.1331 | <0.0001 |
| Globulin (g/L) | 97      | 0.0439 | 0.0395 | 189   | 0.0438 | 0.0039 |
| AG ratio       | 97      | 0.1739 | 0.0002 | 189   | 0.1055 | <0.0001 |
| Log CRP (mg/L) | 79      | 0.2099 | 0.0002 | 169   | 0.1124 | <0.0001 |

https://doi.org/10.1371/journal.pone.0247745.g003

https://doi.org/10.1371/journal.pone.0247745.t004
The MLR limit was 0.474 (95% CI 0.469 to 0.482) and for males was 0.505 (95% CI 0.497 to 0.515). The sensitivities and specificities derived using these values for the different populations are given in S4 Table in S2 File, but positive likelihood ratios were all < 10.

In patients with all forms of TB within the 3-year cohort, six patients had an MLR below the lower cut-off limits, two with culture-positive TB; two had diabetes, one HIV co-infection (culture-positive), one an alcohol problem, one with malnutrition (culture-positive) and one with no co-morbidities. Using the upper MLR cut-off values, the associations observed in the univariate analysis (Table 2) were confirmed. More patients with culture-positive TB from any form of TB had an MLR < 0.65. However, the positive likelihood MLRs in whatever category remained < 10, indicating that the MLR would not be a valuable predictor for TB in common clinical situations.

Table 5. Definition of best diagnostic points from ROC curves.

| Population                      | Sex   | TB (n) | Not TB (n) | AUC ± SE | Best diagnostic point | MLR cut-off value |
|--------------------------------|-------|--------|------------|----------|-----------------------|-------------------|
|                                |       |        |            | Sensitivity | Specificity          |                   |
| Notified initially as TB       | F     | 88     | 23         | 0.55 ± 0.067 | 58.0 | 50.0 | 0.316 |
|                               | M     | 176    | 27         | 0.55 ± 0.058 | 56.0 | 50.0 | 0.381 |
| All screened excluding contacts| F     | 20     | 193        | 0.66 ± 0.069 | 62.5 | 60.0 | 0.289 |
|                               | M     | 56     | 176        | 0.70 ± 0.043 | 61.7 | 70.0 | 0.375 |
| Contacts S+PTB vs S+PTB found at screening | F | 36  | 70 | 0.69 ± 0.056 | 59.6 | 70.0 | 0.333 |
|                               | M     | 44     | 74         | 0.71 ± 0.051 | 61.3 | 70.0 | 0.381 |
| Contacts of S+PTB vs S+PTB     | F     | 102    | 70         | 0.88 ± 0.026 | 76.7 | 85.0 | 0.333 |
|                               | M     | 195    | 74         | 0.93 ± 0.015 | 84.1 | 88.0 | 0.375 |

a Significant difference, P = 0.0266
b Active case-finding only

https://doi.org/10.1371/journal.pone.0247745.t005
site had a high MLR (48/69 (70%) vs. 48/106 (24%); \( \chi^2 = 10.7, P = 0.001 \)) compared to those without a positive culture. More patients with pulmonary disease had MLRs above the upper limit compared to those with extrapulmonary disease (46/94 compared to 44/159; \( \chi^2 = 10.8, P = 0.001 \), see Fig 3). Three patients with miliary TB had MLRs of 0.10 (lymphocytes 5.1 x \( 10^9 \)L), 0.36 and 1.00 (bone marrow depression with lymphocytes and monocytes both with an absolute value of 0.2 x \( 10^9 \)L). Three patients with problem alcohol use and disseminated TB had high MLRs due to lymphopenia (all three had a lymphocyte count of 0.6 x \( 10^9 \)L).

In the group of patients with S+PTB, the MLRs above the cut-off again confirmed the univariate and multiple regression analysis (Table 3): white cell counts >11 x \( 10^9 \)L were more common in those with MLRs above their sex-specific limits (19/96 vs. 10/168; \( \chi^2 = 12.0, P = 0.0006 \)); albumin levels were more commonly <40 g/L in those with a high MLR (80/90 compared to 103/167; \( \chi^2 = 18.9, P = 0.00001 \)) and globulin >32 g/L were higher (80/90 compared to 133/163; \( \chi^2 = 4.9, P = 0.027 \)); C-reactive protein (CRP) levels were high (>10 mg/L) in those with MLRs above the sex-specific limits (74/87 vs. 61/140; \( \chi^2 = 38.3, P < 0.00001 \)) and higher in males with values >10 mg/L than females (Mann-Whitney, \( Z = 2.007, P = 0.045 \)). However, higher ratios were still more frequent in males (130/194 cf. 56/101; \( \chi^2 = 3.81, P = 0.05 \)). Those with high MLRs were more likely to have a sputum smear of 3+ (\( \chi^2 = 9.0, P = 0.0027 \)), but the difference between males and females was not significant. There was no difference in the radiographic extent of disease, but cavitation was more frequent in females with high compared to normal MLRs (\( \chi^2 = 10.0, P = 0.0016 \)) and in males than females with normal MLRs (\( \chi^2 = 9.6, P = 0.00195 \)). High or low MLRs were not associated with drug resistance.

During the same month as the anonymized samples, 8 patients with notified tuberculosis had 11 blood tests (Fig 1). In the various TB clinics, 93 individuals were seen, several on more than one occasion: none with LTBI or cured TB had an MLR above the upper limit for their sex, although one patient with sarcoidosis had an MLR below the lower limit. Those with a positive TST or IGRA did not have higher MLRs than those who were negative.

**Prognostic value of the MLR in those with LTBI**

In contacts of index cases with S+PTB, there was one patient with an MLR of 1.0 who on review was considered to have active TB, based on atelectasis in left lower zone, TST conversion from 6 to 15 mm induration and a CRP of 28 mg/L and whose chest radiograph cleared following treatment for TB (Table 2). Two other patients, who developed culture-positive TB, had MLRs of 0.26 and 0.22 at screening.

There were 11 contacts of S+PTB who showed a completely negative response to tuberculin at their first visit with a positive TST at 6–8 weeks follow-up. Eight of nine with an IGRA were positive (one rising from 0 to 0.5 IU/mL). All these with evidence of recent infection with TB had an MLR within the normal ranges and none developed TB (all received preventive treatment).

In the IGRA+/TST+ screened population without known contact with TB, 8 had a high MLR (S4 Table in S2 File). One had initially been notified as a case of TB being a contact of an uncle, who had active but not pulmonary TB; this person had several risk factors for TB, minor gastro-intestinal symptoms and was given a trial of standard treatment which was stopped at 2 months (2 months of rifampicin and pyrazinamide being a proven preventive treatment for LTBI). The other 7 did not develop TB, having received preventive treatment.

**Deaths and MLR**

There were 29 deaths (1.9%) in notified TB cases from 2005–2017. Three were due to TB, three where TB contributed to death and the remainder were unrelated to TB. MLRs above the sex-
specific limits were found in 18 (62%) but were not significantly higher or more numerous in those where TB played a role (5 males and 1 female) compared to those where there was another cause of death. MLRs measured within a day or two of death did not improve on the predictive value above samples taken at the time of TB diagnosis.

**Effect of treatment on MLRs**

Two-week follow-up MLRs were available for 178 with S+PTB. Five showed no change, 57 were higher and 115 were lower; MLRs were more likely in males than females to fall to the normal range ($\chi^2 = 6.5, P = 0.011$). Looking only at results obtained at the start of treatment, at 2 months and at the end of treatment, there was a significant fall in the MLR by 2 months (paired t-test: $t = 7.5, P < 0.0001, df 136$) and 6 months ($t = 5.3, P < 0.0001, df 117$). Looking at individual patients, a persistently high MLR could not be used to predict who would remain culture-positive at 2 months or have a poor outcome. Four patients had extended inpatient stays and multiple blood tests taken due to their severity of disease. Three showed a reduction in MLR from high to normal values by days 2, 6 and 21 respectively, whilst another showed an MLR which remained high for 247 days. No additional effect was seen in patients with drug-resistant TB.

**Effect of age on MLRs**

In order to determine whether the sex difference might be related to sex hormones or differences in inflammatory responses with age, MLRs were divided into age groups 16–45 years (women should be pre-menopausal), 46–65 years and >65 years. In order to ensure that the level of disease burden was comparable, only those with S+PTB were examined. The 16–45 years age group showed the greatest difference in MLR between the sexes ($P = 0.0035$), although the 46–65 years age group was also significantly different ($P = 0.047$; Fig 4).

**Discussion**

In TB, MLR was associated with a low serum albumin, high white cell count and a positive culture, as well as with high CRP. Males also showed an association with HIV and the serum albumin-to-globulin ratio. In S+PTB, this was refined to a high neutrophil count (females only), with albumin and a high CRP (a significant interaction in males) and male sex. Females with S+PTB also showed a link between MLR and smear and lung cavities. The sensitivity and specificity of MLRs were poor for the diagnosis of TB or as a screening tool to detect active TB in contacts and IGRA+ individuals. High MLRs did not predict the development of TB in screened populations, nor treatment effectiveness, although MLRs usually fell with treatment. MLRs correlated with neutrophil counts in the one month CBC population. High MLRs were more often due to monocytes, especially in males. The sex difference in MLRs was most marked in the 16–45 years age group.

**Sex-specific differences**

Males had higher MLRs than females. Males have more S+PTB, whereas the sex ratio in extra-pulmonary TB is equal [25, 26]. Lung cavities are more common in males than females [27]. Many of the reported data on MLRs either had a predominance of males in the TB group [13, 28] or did not give sex-specific data [18]. The immune response in males is less effective than in females despite greater TLR2 and TLR4 expression, more Th17 cells and CD4+ Treg cells, CD8+ T cells and NK cells [29]. Monocytosis is a feature of infection [23] and high values are found especially in males [24]. Thus, the higher MLRs in males and their association with
more severe forms of TB and with lung cavities might be expected as a sex-specific immune response. Such individuals are more readily diagnosed and regularly bias studies in TB towards a male-predominant population.

Clinical value

The early use of the MLR in TB noted that “the . . . ratio cannot . . . be used as a criterion for diagnosis”, the “monocyte-lymphocyte ratio . . . is not a sensitive index of activity in the tuberculous patient” (activity being measured by the extent of disease, tachycardia, fever, clinical judgment of prognosis and follow-up over two years) and that “a considerable number of patients with tuberculosis will have a normal monocyte-lymphocyte ratio” [30]. These results from the pre-antibiotic era of TB treatment have been confirmed in a modern setting by this study. The association of lymphopenia and a lower MLR with TB in a rabbit model [11, 31] was rarely observed in our study, even in those with miliary disease as the human comparator of the experimental method.

A low or high MLR has been associated with a hazard ratio of 2.47, 1.5 and 1.22 for the development of TB during follow-up of adults with HIV infection before anti-retroviral therapy [14], in HIV-infected post-partum women [15] and in infants [17] in South Africa, respectively. However, the sensitivities of cut-off values were low (< 10%), such that the MLR had little predictive value for an individual person. A higher hazard ratio (4.5) was observed in contacts who went on to develop TB, but a combination of a tuberculin skin test ≥ 14 mm (sensitivity 7.5%) with monocytes > 7.5% of all white blood cells (sensitivity and specificity about 75%) was reported to have a hazard ratio of 8.78, noting that many of the diagnoses of TB were a decision to treat in young children [16]. Using the same criteria from previous studies [16, 28] in our group of contacts, the sensitivities were greater but the specificities were poorer than with our cut-offs and the positive predictive values were lower (S5 and S6 Tables in S2 File).

Limitations

This audit was performed at a single site. However, this ensured that data collection was uniform and follow-up data consistently available. Few patients had HIV co-infection and those with HIV were taking antiretroviral therapy and most had normal lymphocyte counts (four were < 1 x 10^9/L). Children were excluded, but this avoided a bias in terms of empirical treatment for TB and a population in which blood tests are fewer and for highly selected reasons. Those over 65 years of age, excluded in the control group, are likely to have disease co-morbidities, especially malignancy, ischemic heart disease and metabolic syndrome [32, 33], which are associated with higher MLRs. Older persons also experience “inflammaging”, having a higher inflammatory response than younger adults [10, 34, 35].

Generalizability

The use of a real-life group of TB patients and contacts from many ethnic backgrounds encourages extrapolation to the global HIV-uninfected TB population. Analysis of groups by smear and culture status, ensured that both real-life results and data uncontaminated by variations in the diagnosis of “clinical TB” could be obtained.

Implications

This study has shown the importance of sex as a variable in the evaluation of biomarkers. Such differences touch upon lipid and metabolic differences in cardiovascular disease [36], cancer
Biomarkers [37] and studies distinguishing general differences between the proteome [38] and transcriptome [39, 40] between the sexes. Both estrogens and androgens affect immune responses [29, 41]. Our data suggested that the difference in MLRs might be due to sex hormones rather than an X-linked cause or sex-related differences in inflammaging due to the differences seen among the age groups, most especially those aged 16–45 years where differences in sex hormones are most apparent (Fig 5). Thus, diseases with a female or male predominance, such as autoimmune diseases or cancer respectively, may need to address the relative efficacy of diagnostic markers and prognostic indicators between the sexes.

Biomarkers and the sexes are especially problematic in tuberculosis. The male predominance is found almost entirely in S+PTB [25, 26] and therefore patient selection will be affected by the number with this form of disease. The relative ease of diagnosis of this form of TB again means that follow-up studies of, say, those with LTBI who go on to develop TB will mean that prognostic biomarkers will be biased towards males.

Interleukin-6 (IL-6) is important in the mobilization of monocytes from the bone marrow [9]. Transcriptomic studies examining the genetics of high MLRs suggested a link with both IL-6 and interferon type I [18]. However, a closer link has been shown with an IL6/IL6R/CEBP gene module, also associated with monocyte expansion, high CRP and a positive sputum smear [42]. These associations are consistent with the findings of the multivariate analyses in this study.

Transcriptomic data investigating the pathogenesis of active TB disease show sex-specific responses [43, 44]. Estrogens, via the alpha receptor, downgrade IL-6 expression in human monocytes [45]. The 3-gene transcriptomic signature of Sweeney, which performed better than 15 other signatures for discriminating latent from active TB [46], has genes whose expression are all affected by sex. Dual-specificity phosphatase 3 (DUSP3) deletion protects female but not male mice from endotoxin shock due to a dominance of M2 (non-classical and anti-inflammatory) macrophages [47]. Guanylate-binding protein 5 (GBP5) is a marker of IFNγ-
induced classical monocytes [48], which are more frequent in males, and has been found in those who develop innate immunity after an IFN\(\gamma\) response [49]. Kruppel-like factor 2 (KLF-2), in association with the male-dominant cytokines IL-6 and monocyte chemoattractant protein-1, promotes inflammation in response to tumor necrosis factor (induced by mycobacterial lipoarabinomannan) [50]. If biomarker studies select a majority of males and/or those with S+PTB, their value should be less in females and those with more limited disease.

**Conclusion**

The MLR is neither diagnostic nor typical of TB. It shows a bias towards males with S+PTB and other clinical markers of severe disease. These findings might account for its association with S+PTB and its previous popularity as a biomarker in tuberculosis and suggests that other biomarkers may face similar biases.

**Supporting information**

S1 Fig. Monocyte-to-lymphocyte ratio (MLR) and neutrophil count. Comparison of MLR and neutrophil count in 14,533 CBCs. Error bars were too small to be visible.

S2 Fig. QQ plots for log. ML ratios for unselected and those with normal hematological indices. A. All anonymized samples: females n = 9972; males n = 4583. From left to right, QQ plots are separated by sex with females on the top line (B, C, D) and males beneath (E, F, G). B and E are all anonymized samples; C (n = 2661) and F (n = 1593) are those with normal hematological indices, but without any limits for monocytes and lymphocytes; D and G are those with normal hematological indices, but with upper limits of 0.8 x 10\(^9\)/L for monocytes and 4 x 10\(^9\)/L for lymphocytes in females (n = 2550) and males (n = 1426) respectively (TB clinic CBCs not removed).

S3 Fig. Comparison between screened population and CBCs: Effect of choosing different limits for the monocyte and lymphocyte counts. A. MLRs comparing culture-positive TB, LTBI and hospital CBCs with normal hematological indices. B. Log. transformed MLRs: all CBCs. C. Log. transformed MLRs: CBCs with normal hematological indices but no restriction on monocyte or lymphocyte limits. D. Log. transformed MLRs: CBCs with normal hematological indices, monocytes < 0.8 x 10\(^9\)/L and lymphocyte < 4.0 x 10\(^9\)/L.

S1 File. Multivariate analyses of patient predictors and MLR.

S2 File. Collated supplemental tables and figure legends.

S3 File. Anonymised CBCs.

S4 File. Clinical data.

S5 File. Data dictionary.
Acknowledgments

We thank Bala Sirigireddy for providing the hematology data used to define the normal ranges of the monocyte-to-lymphocyte ratio.

Author Contributions

Conceptualization: Thomas S. Buttle, Graham H. Bothamley.

Data curation: Natalie J. Marshall, Viktoria C. Spong, Graham H. Bothamley.

Formal analysis: Thomas S. Buttle, Graham H. Bothamley.

Funding acquisition: Graham H. Bothamley.

Investigation: Thomas S. Buttle, Claire Y. Hummerstone, Thippeswamy Billahalli, Richard J. B. Ward, Korina E. Barnes, Viktoria C. Spong, Graham H. Bothamley.

Methodology: Thomas S. Buttle, Natalie J. Marshall, Viktoria C. Spong, Graham H. Bothamley.

Project administration: Graham H. Bothamley.

Resources: Natalie J. Marshall, Viktoria C. Spong, Graham H. Bothamley.

Supervision: Graham H. Bothamley.

Validation: Thomas S. Buttle.

Visualization: Thomas S. Buttle.

Writing – original draft: Thomas S. Buttle, Graham H. Bothamley.

Writing – review & editing: Claire Y. Hummerstone, Thippeswamy Billahalli, Richard J. B. Ward, Korina E. Barnes, Natalie J. Marshall, Viktoria C. Spong.

References

1. Global tuberculosis report 2019. Geneva: World Health Organization; 2019. Licence: CCNY-NC-SA3.0IGO.

2. WHO meeting report of a technical expert consultation: non-inferiority analysis of Xpert MTB/RIF Ultra compared to Xpert MTB/RIF. Geneva: World Health Organization: 2017 (WHO/HTM/TB/2017.04). License: CC BT-Nc-SA 3.0 IGO.

3. Campbell JR, Winters N, Menzies D. Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis. BMJ 2020; 368: m549. https://doi.org/10.1136/bmj.m549 PMID: 32156698

4. Petruccioli E, Scriba TJ, Petrone L, Hatherill M, Joosten SA, et al. Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. Eur Respir J 2016; 48(5): 1411–1419. https://doi.org/10.1183/13993003.00510-2016 PMID: 27390280

5. Esmail H, Lai RP, Lesosky M, Wilkinson KA, Graham CM, Coussens AK, et al. Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[18F]fluoro-D-glucose positron emission and computed tomography. Nat Med 2016; 22(10): 1090–1093. https://doi.org/10.1038/nm.4161 PMID: 27595321

6. Osawa T, Watanabe M, Morimoto K, Okumura M, Yoshiyama T, Ogata H, et al. Serum procalcitonin levels predict mortality risk in patients with pulmonary tuberculosis: a single-center prospective observational study. J Infect Dis. 2020; jiaa275. https://doi.org/10.1093/infdis/jiaa275 PMID: 32445568

7. Bothamley GH, Beck JS, Schreuder GMTH, D’Amaro J, de Vries RRP, Kardjito T, et al. Association of tuberculosis and M. tuberculosis-specific antibody levels with HLA. J Infect Dis. 1989; 159(3): 549–555. https://doi.org/10.1093/infdis/159.3.549 PMID: 2464654

8. Penn-Nicholson A, Mbandi SK, Thompson E, Mendelsohn SC, Suliman S, Chegou NN, et al. RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response. Sci Rep 2020; 10: 8629. https://doi.org/10.1038/s41598-020-65043-8 PMID: 32451443
23. Zaretsky AG, Engiles JB, Hunter CA. Infection-induced changes in hematopoiesis. J Immunol. 2014; 
21. Eng J. ROC analysis: web-based calculator for ROC curves. Baltimore: John Hopkins University 
20. Buttle T, Bothamley GH. The monocyte to lymphocyte ratio as a biomarker for tuberculosis. Thorax 2018; 
19. Buttle T, Bothamley G. The monocyte to lymphocyte ratio as a biomarker for tuberculosis. Thorax 2018; 73 (Suppl 4): A217. 
18. Buttle T, Bothamley G. The meaning of a high monocyte to lymphocyte ratio in tuberculosis. Eur Respir J. 2019; 54: Suppl. 63: PA5285. 
17. Rakotosamimanana N, Richard V, Raharimanga V, Gicquel B, Doherty TM, Zumla A, et al. Biomarkers for risk of developing active tuberculosis in contacts of TB patients: a prospective cohort study. Eur Respir J. 2019; 46: 1095–1103. https://doi.org/10.1183/13993003.00263-2015 PMID: 26250497 
16. Rakotosamimanana N, Richard V, Raharimanga V, Gicquel B, Doherty TM, Zumla A, et al. Biomarkers for risk of developing active tuberculosis in contacts of TB patients: a prospective cohort study. Eur Respir J. 2019; 46: 1095–1103. https://doi.org/10.1183/13993003.00263-2015 PMID: 26250497 
15. Naranbhai V, Moodley D, Chipato T, Stranix-Chibanda L, Nakabaiti C, Kamateeka M, et al. for the HPTN 046 protocol team. The association between ratio of monocytes:lymphocytes and risk of tuberculosis (TB) amongst HIV infected postpartum women. J Acquir Immune Def Syndr. 2014: 67(5): 573–575. https://doi.org/10.1097/QAI.0000000000000353 PMID: 25247435 
14. Naranbhai V, Hill AV, Abdool Karim SS, Naidoo K, Karim QA, Warimwe GM, et al. Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy. J Infect Dis. 2014; 209: 500–509. https://doi.org/10.1093/infdis/jit494 PMID: 24041796 
13. La Manna MP, Orlando V, Dieli F, Di Carlo P, Cascio A, Cuzzi G, et al. Quantitative and qualitative profiles of circulating monocytes may help identifying tuberculosis infection and disease stages. PLoS ONE 2017; 12(2): e0171358. https://doi.org/10.1371/journal.pone.0171358 PMID: 28208160 
12. Zelmer A, Stockdale L, Prabowo SA, Cia F, Spink N, Eddaoudi A, et al. High monocyte to lymphocyte ratio is associated with impaired protection after subcutaneous administration of BCG in a mouse model of tuberculosis. F1000Research 2018; 7: 296. https://doi.org/10.12688/f1000research.14239.2 eCollection 2018. PMID: 30026926 
11. Doan CA, Sabin FR. The relation of the tubercle and the monocyte:lymphocyte ratio to resistance and susceptibility in tuberculosis. J Exp Med 1930; 52 (6_suppl_3): 113–152. https://rupress.org/jem/issue/52/6_suppl_3. 
10. Kumar BV, Connors TJ, Farber DL. Human T cell development, localization, and function throughout life. Immunity 2018; 48: 202–213. https://doi.org/10.1016/j.immuni.2018.01.007 PMID: 29466753 
9. Evren E, Ringqvist E, Tripathi KP, Sleiens N, Rives IC, Alisjahbana A, et al. Distinct developmental pathways from blood monocytes generate human lung macrophage diversity. Immunity 2021; 54: 259–275. https://doi.org/10.1016/j.immuni.2020.12.003 PMID: 33382972 
8. Holt LR, Mungap Du Plessis M, Sharpe HT, Netten D. The developmental and functional plasticity of human monocytes. Immunity 2018; 48: 202–213. https://doi.org/10.1016/j.immuni.2018.01.007 PMID: 29466753 
7. Wang J, Yin Y, Wang X, Pei H, Kuai S, Gu L, et al. Ratio of monocytes to lymphocytes in peripheral blood in patients diagnosed with active tuberculosis. Braz J Infect Dis. 2015; 19(2): 125–131. https://doi.org/10.1016/j.bjid.2014.10.008 PMID: 25529365 
6. Hensel M, Graedel L, Kutz A, Haubitz S, Huber A, Mueller B, et al. Peripheral mononcytosis as a predictive factor for adverse outcome in the emergency department. Medicine 2017; 96: 28. https://doi.org/10.1016/j.md.2016.09.074 PMID: 28700476 
5. Horton KC, MacPherson P, Houben RM, White RG, Corbett EL. Sex differences in tuberculosis burden in low- and middle-income countries: a systematic review and meta-analysis. PLoS Med. 2016; 13(9): e1002119. https://doi.org/10.1371/journal.pmed.1002119 PMID: 27598345 
4. Hensel M, Gradel L, Kutz A, Haubitz S, Huber A, Mueller B, et al. Peripheral mononcytosis as a predictive factor for adverse outcome in the emergency department. Medicine 2017; 96: 28. https://doi.org/10.1016/j.md.2016.09.074 PMID: 28700476 
3. Ohene SA, Bakker MI, Ojo J, Toonstra A, Awudi D, Klatser P. Extra-pulmonary tuberculosis: a retrospective study of patients in Accra, Ghana. PLoS ONE 2019; 14(1): e0209650. https://doi.org/10.1371/journal.pone.0209650 PMID: 30625188 
2. Aktogu S, Yorgancioglu A, Cirak K, Kose T, Dereli SM. Clinical spectrum of pulmonary and pleural tuberculosis: a report of 5,480 cases. Eur Respir J. 1996; 9: 2031–2035. https://doi.org/10.1183/09031936.96.90102031 PMID: 8902463 
1. Wang J, Yin Y, Wang X, Pei H, Kuai S, Gu L, et al. Ratio of monocytes to lymphocytes in peripheral blood in patients diagnosed with active tuberculosis. Braz J Infect Dis. 2015; 19(2): 125–131. https://doi.org/10.1016/j.bjid.2014.10.008 PMID: 25529365
29. Taneja V. Sex hormones determine immune response. Front Immunol. 2018; 9:1931. https://doi.org/10.3389/fimmu.2018.01931 PMID: 30210492

30. Muller GL, Davidson DL. The monocyte-lymphocyte ratio as a measure of activity in pulmonary tuberculosis. N Engl J Med. 1934; 211: 248–252.

31. Doan CA, Sabin FR. Local progression with spontaneous regression of tuberculosis in the bone marrow of rabbits, correlated with a transitory anemia and leucopenia after intravenous inoculation. J Exp Med. 1927; 46:315–345. https://doi.org/10.1084/jem.46.2.315 PMID: 19869341

32. Catrysse L, van Loog G. Inflammation and the metabolic syndrome: the tissue-specific functions of NF-κB. Trends in Cell Biol. 2017; 27: 417–429. https://doi.org/10.1016/j.tcb.2017.01.006 PMID: 28237661

33. Cho SMJ, Lee H, Shim JS, Kim HC. Sex-, age-, and metabolic disorder-dependent distributions of selected inflammatory biomarkers among community-dwelling adults. Diabetes Metab J. 2020; 44(5): 711–725. https://doi.org/10.4093/dmj.2019.0119 PMID: 32431105

34. Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, et al. Immunosenescent and inflamm-aging as two sides of the same coin: friends or foes? Front Immunol. 2018; 8:1960. https://doi.org/10.3389/fimmu.2017.01960 PMID: 29375577

35. Ault R, Dwivedi V, Koivisto E, Nagy J, Miller K, Nagendran K, et al. Altered monocyte phenotypes but not impaired peripheral T cell immunity may explain susceptibility of the elderly to develop tuberculosis. Experimental Gerontology 2018; 111: 35–44. https://doi.org/10.1016/j.exger.2018.06.029 PMID: 29991459

36. Gerdts E, Regitz-Zagrosek V. Sex differences in cardiometabolic disorders. Nature Med. 2019; 25: 1657–1666. https://doi.org/10.1038/s41591-019-0643-8 PMID: 31700185

37. Yuan Y, Liu L, Chen H, Wang Y, Xu Y, Mao H, et al. Comprehensive characterization of molecular differences in cancer between male and female patients. Cancer Cell. 2016; 29(5): 711–22. https://doi.org/10.1016/j.ccell.2016.04.001 PMID: 27165743

38. Romanov N, Kuhn M, Aebersold R, Ori A, Beck M, Bork P. Disentangling genetic and environmental effects on the proteotypes of individuals. Cell. 2019; 177(5): 1308–18. https://doi.org/10.1016/j.cell.2019.03.015 PMID: 31031010

39. Oliva M, Muñoz-Aguirre M, Kim-Hellmuth S, Wucher V, Gewirtz ADH, Cotter DJ, et al. The impact of sex on gene expression across human tissues. Science 2020; 369: 369. https://doi.org/10.1126/science.aba3066 PMID: 32913072

40. Zaghihoil SB, Kühnel B, Elhadad MA, Kader S, Halama A, Thareja G, et al. Epigenetics meets proteomics in an epigenome-wide association study with circulating blood plasma protein traits. Nat Comm. 2020; 11:15. https://doi.org/10.1038/s41467-019-13831-w PMID: 31900413

41. Gubbels Bupp MR, Jorgensen TN. Androgen-induced immunosuppression. Front Immunol. 2018; 9:794. https://doi.org/10.3389/fimmu.2018.00794 PMID: 29755457

42. Delgobo M, Mendes DAGB, Kozlova E, Lummertz Rocha E, Rodrigues-Luiz GF, Mascarin L, et al. An evolutionary recent IFN/IL-6/CEBP axis is linked to monocyte expansion and tuberculosis severity in humans. eLife 2091; 8: e47013. https://doi.org/10.7554/eLife.47013 PMID: 31637998

43. Bongen E, Lucian H, Khatri A, Fragiadakis GK, Bjornson ZB, Nolan GP, et al. Sex differences in the blood transcriptome identify robust changes in immune cell proportions with aging and influenza infection. Cell Rep. 2019; 29: 1961–1973. https://doi.org/10.1016/j.celrep.2019.03.015 PMID: 31722210

44. Marquez EJ, Chung C-H, Marches R, Rossi RJ, Nehar-Belaid D, Erolgu A, et al. Sexual dimorphism in human immune system aging. Nat Comm. 2020; 11:751. https://doi.org/10.1038/s41467-019-14396-9 PMID: 32029736

45. Pelekanou V, Kampa M, Kiagiadaki F, Deli A, Theodoropoulos P, Agrogiannis G, et al. Estrogen anti-inflammatory activity on human monocytes is mediated between estrogen receptor Erα36 and GPER3/GPER1. J Leukocyte Biol. 2016; 199: 2515–2527. https://doi.org/10.4049/jlb.201510-196RR PMID: 29991459

46. Warsinske H, Vashisht R, Khatri P. Host-response-based gene signatures for tuberculosis diagnosis: a systematic comparison of 16 signatures. PLoS Med. 2019; 16(4):e1002786. https://doi.org/10.1371/journal.pmed.1002786 PMID: 31013272

47. Vandereyken MM, Singh P, Wathieu CP, Jacques S, Zuravskvii T, Dejager L, et al. J Immunol. 2017; 199: 2515–2527. https://doi.org/10.4049/jimmunol.1602092 PMID: 28848068

48. Fujiwara Y, Hizukuri Y, Yamashiro K, Makita N, Ohnishi K, Takeya M, et al. Guanylate-binding protein 5 is a marker of Interferon-γ-induced classically activated macrophages. Clin Transl Immunol. 2016; 5: e111. https://doi.org/10.1038/cit.2016.59 PMID: 27990286

49. Siwek W, Tehrani SSH, Mata JF, Jansen LET. Activation of clustered IFNγ target gene drives cohere-nt-controlled transcriptional memory. Mol Cell 2020; 80: 396–409. https://doi.org/10.1016/j.molcel.2020.10.005 PMID: 33108759
50. Jiang T, Zhang W, Wang Z. Laquinimod protects against TNF-α-induced attachment of monocytes to human aortic endothelial cells (HAECs) by increasing the expression of KLF2. Drug Design, Dev Ther. 2020; 14: 1683–1691. https://doi.org/10.2147/DDDT.S243666 PMID: 32440094